For the pediatric patient, Pediatric: Pain Management. Criteria Common adverse effects across the 3 ketorolac dose groups. Adverse Effects.
Increasing the dose of ketorolac tromethamine beyond the label FDA-Labeled Indications and Dosage (Pediatric). There is limited
Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of
by JY Hong 2024 Cited by 63dose of ketorolac was equipotent to a 0.1 mg/kg dose of morphine when given KETOROLAC AND ACETAMINOPHEN FOR PEDIATRIC POSTOPERATIVE PAIN. 1555.
Ketorolac is not indicated for use in pediatric patients and is not indicated for minor or chronic painful conditions. Increasing the dose of ketorolac beyond
by DRS AMOROSO Cited by 1530mg intranasal ketorolac and a single dose of 30mg intramuscular ketorolac in healthy stratified pharmacokinetics of ketorolac tromethamine in pediatric
Ketoconazole (topical): Pediatric drug information; Ketorolac (ophthalmic): Pediatric drug information; Ketorolac (systemic): Pediatric drug information; Ketotifen (ophthalmic): Pediatric drug information; Ketotifen : Pediatric drug information; Labetalol: Pediatric drug information; Lacosamide: Pediatric drug information
Limited information is available regarding the pharmacokinetics of dosing of ketorolac tromethamine in the pediatric population. Following a single intravenous
Ketorolac (ophthalmic): Pediatric drug information Ketorolac (systemic): Ondansetron: Pediatric drug information Oral rehydration solutions
Comments